GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (FRA:TD5A) » Definitions » Valuation Rank

Tandem Diabetes Care (FRA:TD5A) Valuation Rank


View and export this data going back to 2013. Start your Free Trial

What is Tandem Diabetes Care Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Tandem Diabetes Care Valuation Rank Related Terms

Thank you for viewing the detailed overview of Tandem Diabetes Care's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Tandem Diabetes Care (FRA:TD5A) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (FRA:TD5A) » Definitions » Valuation Rank
Comparable Companies
UFPT TMDX ATEC AHCO PRCT SSII NVCR AVNS ESTA QTRX ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
TNDM:USA
Address
11075 Roselle Street, San Diego, CA, USA, 92121
Website
https://www.tandemdiabetes.com
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.